The Board of Directors of Aster DM Healthcare Limited met on 20 May 2025 and approved the audited financial results (standalone and consolidated) for the quarter and year ended 31 March 2025.
The board recommended a final dividend of ₹1 per equity share of face value ₹10 each for the financial year 2024-25, subject to shareholder approval.
The Board approved the incorporation of three Wholly Owned Subsidiaries and investment therein.
Deloitte Haskins & Sells issued an unmodified opinion on the financial statements.
Standalone Financial Results:
Revenue from operations: ₹2,320.48 crore for the year ended March 31, 2025, as against ₹2,036.50 crore for the year ended March 31, 2024.
Profit after tax: ₹6,208.97 crore for the year ended March 31, 2025, as against ₹156.96 crore for the year ended March 31, 2024.
The company acquired additional 6.91% stake amounting ₹19.76 crores in Prerana Hospital Limited (Aster Aadhar).
Alfaone Medicals Private Limited (AMPL) converted the outstanding inter-company loan, including accrued interest, availed from the Company and issued equity shares and Non-Cumulative Optionally Convertible Redeemable Preference Shares (OCRPS). Consequent to the said issuance, shareholding of the Company in AMPL has increased from 15.98% to 48.91 %.
The transaction related to scheme of amalgamation of Quality Care India Limited with Aster DM Healthcare Limited was completed on 30 April 2025 by acquiring 1,90,46,028 equity shares ofQCIL by the Company from BCP Asia II TopCo Pte Ltd (BCP) and Centella Mauritius Holdings Limited (TPG) for a consideration of INR 849.13 crores. As discharge of the total purchase consideration payable, Aster DM Healthcare has allotted 1,86,07,969 equity shares (face value ~10 each) to BCP and TPG.